Table 1.
Characteristic | Total (n=34) |
---|---|
Demographic | |
Gender (female), n (%) | 17 (50.0) |
Age (years), median (IQR) | 76 (67-83) |
Study period (2010-2017), n (%) | 15 (44.1) |
Study period (2018-2020), n (%) | 19 (55.9) |
Primary tumor, n (%) | |
Proven pathology | 28 (82.4) |
Perihilar cholangiocarcinoma | 25 (73.5) |
Gallbladder carcinoma | 9 (26.5) |
Tumor staging, n (%) | |
Bismuth-Corlette type I | 2 (5.9) |
Bismuth-Corlette type II | 8 (23.5) |
Bismuth-Corlette type IIIa | 4 (11.8) |
Bismuth-Corlette type IIIb | 3 (8.8) |
Bismuth-Corlette type IV | 17 (50.0) |
Distant metastasis | 24 (70.6) |
Ascites | 9 (26.5) |
Portal hypertension | 2 (5.9) |
Serum laboratory test, median (IQR) | |
Total bilirubin (μmol/L) | 226 (121-299) |
C reactive protein (mg/L) | 71 (18-164) |
Previous interventions | |
Previous ERCP, n (%) | 24 (70.6) |
Number of previous ERCP, mean (range) | 2.4 (1-5) |
Number of biliary stents, mean (range) | 1.45 (0-3) |
Percutaneous drainage, n (%) | 2 (5.9) |
Indication for biliary drainage, n (%) | |
Jaundice | 22 (64.7) |
Sepsis without jaundice | 2 (5.9) |
Cholangitis | 10 (29.4) |
Indication for EUS-HGS, n (%) | |
ERCP failure | 22 (64.7) |
Duodenal stricture | 8 (23.5) |
Altered anatomy | 2 (5.9) |
Isolated left hepatic duct dilation | 2 (5.9) |
Oncological status, n (%) | |
Fit for chemotherapy | 22 (64.7) |
Previous chemotherapy | 14 (41.2) |
IQR: Interquartile range, EUS-HGS: EUS-guided hepaticogastrostomy